CHELSEA ENRIGHT: Open Payments
NPI 1831959964 · ATLANTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,252 in 47 payments from 29 companies in 2025. Trend: 2023 $0 · 2024 $619 · 2025 $1,252
Food & beverage: $1,252
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 3 | $155 |
| Incyte Corporation | 5 | $107 |
| Janssen Biotech, Inc. | 4 | $94 |
| AstraZeneca Pharmaceuticals LP | 3 | $79 |
| PFIZER INC. | 3 | $59 |
| GlaxoSmithKline, LLC. | 2 | $55 |
| ABBVIE INC. | 2 | $53 |
| Deciphera Pharmaceuticals Inc. | 2 | $48 |
| Sumitomo Pharma America, Inc. | 2 | $44 |
| SERVIER PHARMACEUTICALS LLC | 2 | $43 |
Products named: RYBREVANT, MONJUVI, QINLOCK, OPDIVO, ORGOVYX, JAKAFI, ELREXFIO, Zoladex.
Industry payments across GA — which companies pay providers there.
